Cargando…
Observational retrospective study of UK national success, risks and costs for 319,105 IVF/ICSI and 30,669 IUI treatment cycles
OBJECTIVE: To compare success rates, associated risks and cost-effectiveness between intrauterine insemination (IUI) and in vitro fertilisation (IVF). DESIGN: Retrospective observational study. SETTING: The UK from 2012 to 2016. PARTICIPANTS: Data from Human Fertilisation and Embryology Authority’s...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076239/ https://www.ncbi.nlm.nih.gov/pubmed/32184314 http://dx.doi.org/10.1136/bmjopen-2019-034566 |
_version_ | 1783507181726859264 |
---|---|
author | Bahadur, Gulam Homburg, Roy Bosmans, Judith E Huirne, Judith A F Hinstridge, Peter Jayaprakasan, Kanna Racich, Paul Alam, Rakib Karapanos, Ioannis Illahibuccus, Afeeza Al-Habib, Ansam Jauniaux, Eric |
author_facet | Bahadur, Gulam Homburg, Roy Bosmans, Judith E Huirne, Judith A F Hinstridge, Peter Jayaprakasan, Kanna Racich, Paul Alam, Rakib Karapanos, Ioannis Illahibuccus, Afeeza Al-Habib, Ansam Jauniaux, Eric |
author_sort | Bahadur, Gulam |
collection | PubMed |
description | OBJECTIVE: To compare success rates, associated risks and cost-effectiveness between intrauterine insemination (IUI) and in vitro fertilisation (IVF). DESIGN: Retrospective observational study. SETTING: The UK from 2012 to 2016. PARTICIPANTS: Data from Human Fertilisation and Embryology Authority’s freedom of information request for 2012–2016 for IVF/ICSI (intracytoplasmic sperm injection)and IUI as practiced in 319 105 IVF/ICSI and 30 669 IUI cycles. Direct-cost calculations for maternal and neonatal expenditure per live birth (LB) was constructed using the cost of multiple birth model, with inflation-adjusted Bank of England index-linked data. A second direct-cost analysis evaluating the incremental cost-effective ratio (ICER) was modelled using the 2016 national mean (baseline) IVF and IUI success rates. OUTCOME MEASURES: LB, risks from IVF and IUI, and costs to gain 1 LB. RESULTS: This largest comprehensive analysis integrating success, risks and costs at a national level shows IUI is safer and more cost-effective than IVF treatment. IVF LB/cycle success was significantly better than IUI at 26.96% versus 11.49% (p<0.001) but the IUI success is much closer to IVF at 2.35:1, than previously considered. IVF remains a significant source of multiple gestation pregnancy (MGP) compared with IUI (RR (Relative Risk): 1.45 (1.31 to 1.60), p<0.001) as was the rate of twins (RR: 1.58, p<0.001). In 2016, IVF maternal and neonatal cost was £115 082 017 compared with £2 940 196 for IUI and this MGP-related perinatal cost is absorbed by the National Health Services. At baseline tariffs and success rates IUI was £42 558 cheaper than IVF to deliver 1LB with enhanced benefits with small improvements in IUI. Reliable levels of IVF-related MGP, OHSS (ovarian hyperstimulation syndrome), fetal reductions and terminations are revealed. CONCLUSION: IUI success rates are much closer to IVF than previously reported, more cost-effective in delivering 1 LB, and associated with lower risk of complications for maternal and neonatal complications. It is prudent to offer IUI before IVF nationally. |
format | Online Article Text |
id | pubmed-7076239 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-70762392020-03-20 Observational retrospective study of UK national success, risks and costs for 319,105 IVF/ICSI and 30,669 IUI treatment cycles Bahadur, Gulam Homburg, Roy Bosmans, Judith E Huirne, Judith A F Hinstridge, Peter Jayaprakasan, Kanna Racich, Paul Alam, Rakib Karapanos, Ioannis Illahibuccus, Afeeza Al-Habib, Ansam Jauniaux, Eric BMJ Open Reproductive Medicine OBJECTIVE: To compare success rates, associated risks and cost-effectiveness between intrauterine insemination (IUI) and in vitro fertilisation (IVF). DESIGN: Retrospective observational study. SETTING: The UK from 2012 to 2016. PARTICIPANTS: Data from Human Fertilisation and Embryology Authority’s freedom of information request for 2012–2016 for IVF/ICSI (intracytoplasmic sperm injection)and IUI as practiced in 319 105 IVF/ICSI and 30 669 IUI cycles. Direct-cost calculations for maternal and neonatal expenditure per live birth (LB) was constructed using the cost of multiple birth model, with inflation-adjusted Bank of England index-linked data. A second direct-cost analysis evaluating the incremental cost-effective ratio (ICER) was modelled using the 2016 national mean (baseline) IVF and IUI success rates. OUTCOME MEASURES: LB, risks from IVF and IUI, and costs to gain 1 LB. RESULTS: This largest comprehensive analysis integrating success, risks and costs at a national level shows IUI is safer and more cost-effective than IVF treatment. IVF LB/cycle success was significantly better than IUI at 26.96% versus 11.49% (p<0.001) but the IUI success is much closer to IVF at 2.35:1, than previously considered. IVF remains a significant source of multiple gestation pregnancy (MGP) compared with IUI (RR (Relative Risk): 1.45 (1.31 to 1.60), p<0.001) as was the rate of twins (RR: 1.58, p<0.001). In 2016, IVF maternal and neonatal cost was £115 082 017 compared with £2 940 196 for IUI and this MGP-related perinatal cost is absorbed by the National Health Services. At baseline tariffs and success rates IUI was £42 558 cheaper than IVF to deliver 1LB with enhanced benefits with small improvements in IUI. Reliable levels of IVF-related MGP, OHSS (ovarian hyperstimulation syndrome), fetal reductions and terminations are revealed. CONCLUSION: IUI success rates are much closer to IVF than previously reported, more cost-effective in delivering 1 LB, and associated with lower risk of complications for maternal and neonatal complications. It is prudent to offer IUI before IVF nationally. BMJ Publishing Group 2020-03-16 /pmc/articles/PMC7076239/ /pubmed/32184314 http://dx.doi.org/10.1136/bmjopen-2019-034566 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Reproductive Medicine Bahadur, Gulam Homburg, Roy Bosmans, Judith E Huirne, Judith A F Hinstridge, Peter Jayaprakasan, Kanna Racich, Paul Alam, Rakib Karapanos, Ioannis Illahibuccus, Afeeza Al-Habib, Ansam Jauniaux, Eric Observational retrospective study of UK national success, risks and costs for 319,105 IVF/ICSI and 30,669 IUI treatment cycles |
title | Observational retrospective study of UK national success, risks and costs for 319,105 IVF/ICSI and 30,669 IUI treatment cycles |
title_full | Observational retrospective study of UK national success, risks and costs for 319,105 IVF/ICSI and 30,669 IUI treatment cycles |
title_fullStr | Observational retrospective study of UK national success, risks and costs for 319,105 IVF/ICSI and 30,669 IUI treatment cycles |
title_full_unstemmed | Observational retrospective study of UK national success, risks and costs for 319,105 IVF/ICSI and 30,669 IUI treatment cycles |
title_short | Observational retrospective study of UK national success, risks and costs for 319,105 IVF/ICSI and 30,669 IUI treatment cycles |
title_sort | observational retrospective study of uk national success, risks and costs for 319,105 ivf/icsi and 30,669 iui treatment cycles |
topic | Reproductive Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076239/ https://www.ncbi.nlm.nih.gov/pubmed/32184314 http://dx.doi.org/10.1136/bmjopen-2019-034566 |
work_keys_str_mv | AT bahadurgulam observationalretrospectivestudyofuknationalsuccessrisksandcostsfor319105ivficsiand30669iuitreatmentcycles AT homburgroy observationalretrospectivestudyofuknationalsuccessrisksandcostsfor319105ivficsiand30669iuitreatmentcycles AT bosmansjudithe observationalretrospectivestudyofuknationalsuccessrisksandcostsfor319105ivficsiand30669iuitreatmentcycles AT huirnejudithaf observationalretrospectivestudyofuknationalsuccessrisksandcostsfor319105ivficsiand30669iuitreatmentcycles AT hinstridgepeter observationalretrospectivestudyofuknationalsuccessrisksandcostsfor319105ivficsiand30669iuitreatmentcycles AT jayaprakasankanna observationalretrospectivestudyofuknationalsuccessrisksandcostsfor319105ivficsiand30669iuitreatmentcycles AT racichpaul observationalretrospectivestudyofuknationalsuccessrisksandcostsfor319105ivficsiand30669iuitreatmentcycles AT alamrakib observationalretrospectivestudyofuknationalsuccessrisksandcostsfor319105ivficsiand30669iuitreatmentcycles AT karapanosioannis observationalretrospectivestudyofuknationalsuccessrisksandcostsfor319105ivficsiand30669iuitreatmentcycles AT illahibuccusafeeza observationalretrospectivestudyofuknationalsuccessrisksandcostsfor319105ivficsiand30669iuitreatmentcycles AT alhabibansam observationalretrospectivestudyofuknationalsuccessrisksandcostsfor319105ivficsiand30669iuitreatmentcycles AT jauniauxeric observationalretrospectivestudyofuknationalsuccessrisksandcostsfor319105ivficsiand30669iuitreatmentcycles |